Literature DB >> 27718182

Overview of Vaccine Adjuvants: Introduction, History, and Current Status.

Ruchi R Shah1, Kimberly J Hassett2, Luis A Brito3.   

Abstract

Adjuvants are included in sub-unit or recombinant vaccines to enhance the potency of poorly immunogenic antigens. Adjuvant discovery is as complex as it is a multidiscplinary intersection of formulation science, immunology, toxicology, and biology. Adjuvants such as alum, which have been in use for the past 90 years, have illustrated that adjuvant research is a methodical process. As science advances, new analytical tools are developed which allows us to delve deeper into the various mechanisms that generates a potent immune response. Additionally, these new techniques help the field learn about our existing vaccines and what makes them safe, and effective, allowing us to leverage that in the next generation of vaccines. Our goal in this chapter is to define the concept, need, and mechanism of adjuvants in the vaccine field while describing its history, present use, and future prospects. More details on individual adjuvants and their formulation, development, mechanism, and use will be covered in depth in the next chapters.

Keywords:  Adjuvant; Alum; Immunopotentiator; Nanoemulsion; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 27718182     DOI: 10.1007/978-1-4939-6445-1_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  22 in total

1.  Specific T cell induction using iron oxide based nanoparticles as subunit vaccine adjuvant.

Authors:  Lázaro Moreira Marques Neto; Nicholas Zufelato; Ailton Antônio de Sousa-Júnior; Monalisa Martins Trentini; Adeliane Castro da Costa; Andris Figueiroa Bakuzis; André Kipnis; Ana Paula Junqueira-Kipnis
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

2.  Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice.

Authors:  Ying Wang; Lijing Su; Matthew D Morin; Brian T Jones; Yuto Mifune; Hexin Shi; Kuan-Wen Wang; Xiaoming Zhan; Aijie Liu; Jianhui Wang; Xiaohong Li; Miao Tang; Sara Ludwig; Sara Hildebrand; Kejin Zhou; Daniel J Siegwart; Eva Marie Y Moresco; Hong Zhang; Dale L Boger; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-27       Impact factor: 11.205

Review 3.  Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.

Authors:  Sara A Taleb; Asmaa A Al Thani; Khalid Al Ansari; Hadi M Yassine
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-06       Impact factor: 3.267

Review 4.  An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.

Authors:  Alessio Facciolà; Giuseppa Visalli; Antonio Laganà; Angela Di Pietro
Journal:  Vaccines (Basel)       Date:  2022-05-22

Review 5.  Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies.

Authors:  Shuen-Iu Hung; Ivan Arni C Preclaro; Wen-Hung Chung; Chuang-Wei Wang
Journal:  Biomedicines       Date:  2022-05-28

Review 6.  Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.

Authors:  Shelan Liu; Min Kang; Na Zhao; Yali Zhuang; Shijian Li; Tie Song
Journal:  Med Rev (Berl)       Date:  2022-05-25

Review 7.  Using PAMPs and DAMPs as adjuvants in cancer vaccines.

Authors:  Huanyou Sun; Wenwen Hu; Yinan Yan; Zichun Zhang; Yuxin Chen; Xuefan Yao; Ling Teng; Xinyuan Wang; Dafei Chai; Junnian Zheng; Gang Wang
Journal:  Hum Vaccin Immunother       Date:  2021-09-14       Impact factor: 4.526

8.  SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?

Authors:  Madeleine R Heldman; Ajit P Limaye
Journal:  J Am Soc Nephrol       Date:  2021-03-24       Impact factor: 10.121

Review 9.  Development of a novel mechanism-based glycolipid adjuvant for vaccination.

Authors:  Jordana Grazziela Coelho-Dos-Reis; Xiangming Li; Moriya Tsuji
Journal:  F1000Res       Date:  2018-05-30

10.  Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice.

Authors:  Jing Huang; Jing Zhou; Reem Ghinnagow; Toshiyuki Seki; Sho Iketani; Daphnée Soulard; Patrick Paczkowski; Yukiko Tsuji; Sean MacKay; Luis Javier Cruz; François Trottein; Moriya Tsuji
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.